Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2020-02-12 Director's Dealing
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
109年01月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings of company insiders, including directors, supervisors, general managers, and their family members. It lists the number of shares held, changes in holdings, and other related information. There is no indication of financial statements, earnings data, or management discussion. The content is focused on insider shareholdings and transactions. This matches the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives (insider trades). The document length is substantial and contains actual data, not just an announcement or certification. Therefore, the appropriate classification is DIRS.
2020-02-12 Chinese
109年01月董事會成員及持股
Major Shareholding Notification Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders, including directors, supervisors, and senior management, showing their current holdings, pledged shares, and related party holdings. It is a disclosure of insider shareholdings and pledges rather than a financial report or announcement of voting results. There is no indication of a meeting, voting, or financial results. The document is a regulatory disclosure about insider shareholdings, which fits best under the category of Major Shareholding Notification (MRQ) as it reports on significant share ownership by insiders and related parties.
2020-02-12 Chinese
109年1月營業收入
Regulatory Filings Classification · 95% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 杏輝 for the period 民國109年01月 (January 2020). It contains financial data such as revenue amounts, year-over-year changes, and notes on accounting standards (IFRS). The document is very short (772 characters) and appears to be a periodic financial summary rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It also does not fit other categories like earnings release or investor presentation. Given the nature of the data and the short length, this is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2020-02-10 Chinese
109年1月背書保證與資金貸與
Regulatory Filings Classification · 90% confidence The document contains financial data related to loan balances, endorsements, and guarantees for a company and its subsidiaries, presented in a tabular format. The content is brief (615 characters) and focuses on specific financial information about guarantees and loans, without comprehensive financial statements or management discussion. It does not appear to be a full financial report like an Annual Report (10-K) or Interim Report (IR). It also does not fit categories like audit reports, earnings releases, or management reports. Given the nature of the data and the brevity, it is likely a Regulatory Filing (RNS) as a general regulatory announcement or compliance disclosure that does not fit other specific categories.
2020-02-10 Chinese
1090210-1-代重要子公司杏輝天力藥業公司獲得復工許可
Regulatory Filings Classification · 95% confidence The document is a short announcement from a listed company (杏輝) regarding its subsidiary 杏輝天力藥業公司 receiving government approval to resume work after a COVID-19 related shutdown. The content is factual, brief, and relates to operational status updates rather than financial results, governance, or regulatory filings. It does not contain financial data, management discussion, or detailed report content. The document length is only 702 characters, indicating it is a brief announcement. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a voting result, capital change, or legal proceeding. The closest fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-02-10 Chinese
係因本公司有價證券於集中交易市場達公布注意交易資訊標準 ，故公布相關財務業務等重大訊息，以利投資人區別瞭解
Regulatory Filings Classification · 95% confidence The document is a short announcement from a listed company (杏輝) disclosing recent financial performance data including revenue, pre-tax profit, net profit, and earnings per share for recent periods. It references that the financial data is unaudited and for investor reference. The document is only 1366 characters long and does not contain full financial statements or detailed analysis. It is a regulatory disclosure of material financial information due to securities trading thresholds, typical of a Regulatory Filing (RNS). It is not a full Annual Report, Interim Report, or Earnings Release, nor is it a report publication announcement since it contains substantive financial data. Therefore, the best classification is Regulatory Filings (RNS).
2020-02-04 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.